Relay Therapeutics reports FY2021 net loss of $363.9M; cash $958M into 2025

Relay Therapeutics, Inc.

2022-FY EPS reported -$3.82 revenue$30,290,000

Q4 net loss $67.5M vs net income $35.3M in Q4 2020; full-year net loss $363.9M ($3.82 loss per share).
Cash, cash equivalents and investments $958.1M at Dec 31 2021, expected to fund operations into at least 2025.
R&D expenses $172.7M for FY2021 (up from $99.9M in FY2020), driven by clinical trial and employee costs.
Announced interim data for RLY-4008 (FGFR2 inhibitor) showing tumor shrinkage in all six treatment-naïve FGFR2 fusion+ cholangiocarcinoma patients.
Dosed first patient in RLY-2608 (pan-mutant PI3Kα inhibitor) first-in-human trial; FDA granted orphan drug designation for RLY-4008 in cholangiocarcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.